Endra Life Sciences Inc Reports Results For The Quarter Ended March 31: Earnings Summary

ENDRA Life Sciences

15/05/2025 21:48

ENDRA Life Sciences Inc NDRA.OQ reported a quarterly adjusted loss of $1.86​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-455.00.  The lone analyst forecast for the quarter was for a loss of $3.91 per share.

Reported revenue was zero​; analysts expected zero.

ENDRA Life Sciences Inc's reported EPS for the quarter was a loss of $1.86​.

The company reported a quarterly loss of $1.04 million.

ENDRA Life Sciences Inc shares had fallen by 23.7% this quarter and lost 50.0% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 4.2% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for ENDRA Life Sciences Inc is $50.00

This summary was machine generated from LSEG data May 15 at 08:48 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-3.91
-1.86
Beat
Dec. 31 2024
-4.10
Sep. 30 2024
-62.30
-9.54
Beat
Jun. 30 2024
-1.22 hundred
-1.40 hundred
Missed